This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
dengue virus | 826 |
virus infection | 294 |
denv infection | 289 |
zika virus | 185 |
viral rna | 177 |
west nile | 141 |
infected cells | 129 |
dengue fever | 124 |
antiviral activity | 121 |
nile virus | 115 |
chikungunya virus | 114 |
virus replication | 113 |
hemorrhagic fever | 111 |
viral replication | 104 |
dengue viruses | 102 |
vero cells | 102 |
dengue hemorrhagic | 98 |
dengue infection | 96 |
public health | 92 |
aedes aegypti | 89 |
immune response | 89 |
virus type | 84 |
encephalitis virus | 76 |
viral infection | 71 |
zikv infection | 70 |
denv replication | 70 |
yellow fever | 70 |
denv serotypes | 67 |
immune responses | 61 |
japanese encephalitis | 60 |
nucleic acid | 58 |
rna replication | 57 |
pcr assay | 56 |
neutralizing antibodies | 56 |
dengue vaccine | 56 |
reverse transcription | 55 |
isothermal amplification | 55 |
severe dengue | 54 |
host cells | 53 |
host factors | 53 |
cell lines | 53 |
dependent enhancement | 52 |
infectious diseases | 52 |
time rt | 51 |
cell line | 51 |
rna viruses | 50 |
cord uid | 50 |
aedes albopictus | 50 |
doc id | 50 |
innate immune | 50 |
porcupine dates | 49 |
respiratory syndrome | 48 |
disease severity | 48 |
cell culture | 48 |
years old | 48 |
blood donors | 48 |
vector control | 47 |
amino acid | 47 |
host cell | 47 |
denv ns | 46 |
nonstructural protein | 45 |
four denv | 45 |
replication complex | 45 |
fever virus | 45 |
envelope protein | 45 |
dengue disease | 44 |
virus infections | 44 |
nlrp inflammasome | 44 |
denv rna | 44 |
inflammasome activation | 44 |
fubc protein | 44 |
mediated isothermal | 43 |
shock syndrome | 43 |
inhibitory factor | 43 |
dendritic cells | 43 |
type i | 42 |
rna synthesis | 41 |
lamp assay | 41 |
structural proteins | 40 |
macrophage migration | 40 |
dengue infections | 40 |
pcr system | 40 |
hela cells | 39 |
endoplasmic reticulum | 39 |
migration inhibitory | 38 |
mosquito cells | 38 |
performed using | 38 |
vascular leakage | 38 |
virus serotype | 38 |
viral infections | 38 |
risk factors | 38 |
influenza virus | 37 |
dengue shock | 37 |
mg ml | 37 |
rna virus | 36 |
clinical manifestations | 36 |
acute respiratory | 36 |
denv infections | 36 |
binding protein | 35 |
virus particles | 35 |
rapid detection | 35 |
viral protein | 35 |
severe acute | 34 |
eid agents | 34 |
puerto rico | 33 |
virus ns | 33 |
infectious disease | 33 |
ns protein | 33 |
phylogenetic analysis | 33 |
membrane vesicles | 33 |
immune complexes | 33 |
previously described | 33 |
monoclonal antibodies | 33 |
antiviral effect | 33 |
flavivirus infections | 32 |
virus entry | 32 |
denv rt | 32 |
monoclonal antibody | 32 |
time pcr | 32 |
guangdong province | 32 |
mass spectrometry | 32 |
four serotypes | 32 |
dengue type | 31 |
clinical samples | 31 |
health organization | 31 |
well plates | 31 |
denv serotype | 31 |
cell death | 31 |
viral genome | 31 |
structural protein | 30 |
syndrome coronavirus | 30 |
virus transmission | 30 |
genotype i | 30 |
world health | 30 |
membrane fusion | 30 |
chain reaction | 29 |
based assay | 29 |
ns antigen | 29 |
sybr green | 29 |
ea fraction | 29 |
mammalian cells | 29 |
endothelial cells | 29 |
febrile illness | 29 |
borne encephalitis | 28 |
human immunodeficiency | 28 |
immunodeficiency virus | 28 |
dengue viral | 28 |
dengue cases | 28 |
herpes simplex | 28 |
complement activation | 28 |
polymerase chain | 28 |
pfu ml | 28 |
real time | 28 |
antibody response | 28 |
life cycle | 27 |
rna binding | 27 |
serum samples | 27 |
united states | 27 |
domain iii | 27 |
mif secretion | 27 |
type virus | 27 |
ag mice | 27 |
gene expression | 27 |
severe disease | 26 |
protein expression | 26 |
infectious virus | 26 |
nonstructural proteins | 26 |
may also | 26 |
flavivirus infection | 26 |
dhf dss | 26 |
post infection | 26 |
viral proteins | 26 |
stranded rna | 25 |
cells treated | 25 |
virus nonstructural | 25 |
endemic areas | 25 |
days post | 25 |
cells infected | 25 |
dengue patients | 25 |
borne viral | 25 |
peripheral blood | 25 |
fusion loop | 24 |
rna interference | 24 |
ns gene | 24 |
virus titer | 24 |
virus serotypes | 24 |
electrode surface | 24 |
molecular evolution | 24 |
simplex virus | 24 |
viral particles | 24 |
fully automated | 23 |
infected patients | 23 |
highly conserved | 23 |
induced autophagy | 23 |
pregnant women | 22 |
acute phase | 22 |
inhibitory effect | 22 |
room temperature | 22 |
severe cases | 22 |
rna polymerase | 22 |
high mannose | 22 |
tetravalent dengue | 22 |
ns protease | 22 |
virus rna | 22 |
protein ns | 22 |
taken together | 22 |
virucidal activity | 22 |
adaptive immune | 22 |
results showed | 22 |
statistically significant | 21 |
aedes mosquitoes | 21 |
igg antibodies | 21 |
dengue haemorrhagic | 21 |
global distribution | 21 |
reporter system | 21 |
southeast asia | 21 |
present study | 21 |
haemorrhagic fever | 21 |
treated cells | 21 |
vaccine development | 21 |
viral load | 21 |
first time | 21 |
antiviral activities | 21 |
hepg cells | 21 |
impedance signal | 21 |
replication complexes | 20 |
severe fever | 20 |
virus envelope | 20 |
chikv infection | 20 |
family flaviviridae | 20 |
amino acids | 20 |
neutralizing antibody | 20 |
dependent manner | 20 |
respiratory syncytial | 20 |
zika fever | 20 |
cell surface | 20 |
life technologies | 20 |
innate immunity | 20 |
denv igm | 20 |
results suggest | 20 |
residual spraying | 20 |
indoor residual | 20 |
virus production | 20 |
disease control | 20 |
positive selection | 19 |
severe denv | 19 |
envelope glycoprotein | 19 |
reduction neutralization | 19 |
human monocytes | 19 |
high levels | 19 |
quantitative rt | 19 |
middle east | 19 |
authors declare | 19 |
selection pressure | 19 |
measles virus | 19 |
binding proteins | 19 |
blood safety | 19 |
arboviral diseases | 19 |
membrane rearrangements | 19 |
rna genome | 19 |
reporter systems | 19 |
cells transfected | 19 |
automated pcr | 19 |
clinical trials | 19 |
french polynesia | 19 |
blood samples | 19 |
plaque assay | 19 |
strand rna | 19 |
chikungunya fever | 19 |
sample size | 19 |
solomon islands | 19 |
animal models | 18 |
recombinant fubc | 18 |
western blotting | 18 |
open reading | 18 |
reporter gene | 18 |
heart diseases | 18 |
thrombocytopenia syndrome | 18 |
human serum | 18 |
time reverse | 18 |
semliki forest | 18 |
syncytial virus | 18 |
different genotypes | 18 |
new guinea | 18 |
clinical trial | 18 |
samples collected | 18 |
phylogenetic tree | 18 |
serially diluted | 18 |
systematic review | 18 |
hcv infection | 18 |
cell monolayers | 18 |
immune system | 18 |
dependent rna | 18 |
electron microscopy | 18 |
analysis using | 18 |
capsid protein | 18 |
control measures | 18 |
live attenuated | 17 |
lipid droplets | 17 |
immune cells | 17 |
clinical diagnosis | 17 |
denv transmission | 17 |
bovine serum | 17 |
wnv infection | 17 |
per year | 17 |
mm cbx | 17 |
acute febrile | 17 |
secondary denv | 17 |
cell responses | 17 |
denv particles | 17 |
folic acid | 17 |
plaque reduction | 17 |
domain ii | 17 |
plasma membrane | 17 |
significantly decreased | 17 |
dengue outbreak | 17 |
genus flavivirus | 17 |
age group | 17 |
reverse transcriptase | 17 |
different concentrations | 17 |
dengue epidemics | 17 |
early clinical | 17 |
copies reaction | 17 |
replication factories | 17 |
reading frame | 17 |
cell viability | 17 |
flaviviridae family | 16 |
virus attachment | 16 |
sars coronavirus | 16 |
virus vaccine | 16 |
indicated time | 16 |
another study | 16 |
forest virus | 16 |
virus strains | 16 |
higher proportion | 16 |
tannic acid | 16 |
progeny virions | 16 |
vertical transmission | 16 |
swine fever | 16 |
er stress | 16 |
serotype specific | 16 |
ns proteins | 16 |
described previously | 16 |
houttuynia cordata | 16 |
human mobility | 16 |
cbx treatment | 16 |
various concentrations | 16 |
sindbis virus | 16 |
visceral leishmaniasis | 16 |
virus infectivity | 16 |
borne diseases | 16 |
disease virus | 16 |
aegypti mosquitoes | 15 |
determined using | 15 |
rna rna | 15 |
tannic acids | 15 |
global public | 15 |
acute dengue | 15 |
selective autophagy | 15 |
vesicular stomatitis | 15 |
viral disease | 15 |
mouse model | 15 |
age groups | 15 |
classical swine | 15 |
virus particle | 15 |
laboratory diagnosis | 15 |
significantly higher | 15 |
closely related | 15 |
antigen presentation | 15 |
tissue culture | 15 |
clinical symptoms | 15 |
primary human | 15 |
antiviral drugs | 15 |
time points | 15 |
fusion protein | 15 |
culture medium | 15 |
endemic area | 15 |
specific rt | 15 |
secretory pathway | 15 |
rna copies | 15 |
cytokine storm | 15 |
agarose gel | 15 |
membrane structures | 15 |
flow cytometry | 15 |
ms identified | 15 |
important role | 15 |
nucleotide sequences | 15 |
stomatitis virus | 15 |
sri lanka | 15 |
recent study | 15 |
tropical medicine | 15 |
transcription loop | 15 |
infectious viral | 15 |
three structural | 15 |
prospective study | 15 |
east respiratory | 14 |
nervous system | 14 |
way anova | 14 |
plasma leakage | 14 |
dengue activity | 14 |
blood mononuclear | 14 |
neutralization test | 14 |
informed consent | 14 |
two different | 14 |
wnv kun | 14 |
south america | 14 |
also observed | 14 |
virus neutralization | 14 |
antiviral response | 14 |
molecular epidemiology | 14 |
denv diii | 14 |
several studies | 14 |
additional file | 14 |
reporter virus | 14 |
membranous replication | 14 |
maturation process | 14 |
diagnostic tests | 14 |
blood transfusion | 14 |
nets formation | 14 |
independent experiments | 14 |
mononuclear cells | 14 |
based reporter | 14 |
bc loop | 14 |
mouse models | 14 |
infected individuals | 14 |
dengue antibodies | 14 |
ifitm protein | 14 |
mosquito vectors | 14 |
negative control | 14 |
com scientificreports | 14 |
broadly neutralizing | 14 |
fetal bovine | 14 |
mosquito control | 14 |
endemic countries | 14 |
cellular proteins | 14 |
human monoclonal | 14 |
genotype ii | 14 |
replication cycle | 14 |
linked immunosorbent | 14 |
automated pockit | 13 |
neutrophil extracellular | 13 |
vascular permeability | 13 |
immunosorbent assay | 13 |
risk factor | 13 |
control group | 13 |
latin america | 13 |
virucidal effect | 13 |
forming assay | 13 |
syndrome virus | 13 |
recent studies | 13 |
methanol crude | 13 |
gel electrophoresis | 13 |
pockit central | 13 |
lateral flow | 13 |
membrane protein | 13 |
untranslated region | 13 |
previous study | 13 |
ns ag | 13 |
clinical features | 13 |
antiviral drug | 13 |
genotype iii | 13 |
maximum likelihood | 13 |
statistical analysis | 13 |
emerging infectious | 13 |
subtropical regions | 13 |
ns serotype | 13 |
measured using | 13 |
four dengue | 13 |
clinical management | 13 |
neutralizing activity | 13 |
i ifn | 13 |
type ii | 13 |
selected studies | 13 |
chronic comorbidities | 13 |
denv envelope | 13 |
reporter protein | 13 |
recent years | 13 |
study demonstrated | 13 |
infection enhancement | 13 |
crucial role | 13 |
complement receptor | 13 |
chinese blood | 13 |
antibody responses | 13 |
cdc real | 12 |
hr post | 12 |
human macrophages | 12 |
infected cell | 12 |
autochthonous dengue | 12 |
blood cells | 12 |
day post | 12 |
i i | 12 |
dengue severity | 12 |
uprt cells | 12 |
cell membranes | 12 |
dengue serotypes | 12 |
central nervous | 12 |
dengue ns | 12 |
prm protein | 12 |
phase i | 12 |
standard plaque | 12 |
plasma samples | 12 |
secondary infection | 12 |
simultaneous detection | 12 |
genome replication | 12 |
based biosensor | 12 |
clinical signs | 12 |
replication sites | 12 |
viral particle | 12 |
global health | 12 |
molecular evolutionary | 12 |
scorpion venom | 12 |
fever dengue | 12 |
spectrum antiviral | 12 |
enveloped viruses | 12 |
epidemiological data | 12 |
immune complex | 12 |
dengue vaccines | 12 |
may lead | 12 |
detect denv | 12 |
copy number | 12 |
secondary infections | 12 |
lipase activity | 12 |
vaccine candidates | 12 |
among blood | 12 |
pcr systems | 12 |
dengue serotype | 12 |
strains isolated | 12 |
denv genome | 12 |
positive control | 12 |
cell lysates | 12 |
denv induced | 12 |
huvec cells | 12 |
ifitm proteins | 12 |
antiviral effects | 12 |
mice infected | 12 |
virus detection | 12 |
billion people | 12 |
congenital zika | 12 |
suckling mice | 12 |
bhk cells | 12 |
autophagy machinery | 12 |
dna vaccine | 12 |
tertiary care | 12 |
two viral | 11 |
acid extraction | 11 |
amplification assay | 11 |
different lineages | 11 |
supplementary material | 11 |
immune evasion | 11 |
pcr assays | 11 |
exosomes derived | 11 |
csp bj | 11 |
serum specimens | 11 |
rapid spread | 11 |
insect cells | 11 |
signal response | 11 |
mtt assay | 11 |
health problem | 11 |
fisher scientific | 11 |
dengue envelope | 11 |
early stage | 11 |
antiviral therapy | 11 |
crude extracts | 11 |
control study | 11 |
virus outbreak | 11 |
molecular mechanisms | 11 |
viral amplification | 11 |
infection dengue | 11 |
infected patient | 11 |
zikv infections | 11 |
unfolded protein | 11 |
dengue pathogenesis | 11 |
also found | 11 |
specific antibodies | 11 |
mm tris | 11 |
clinical presentation | 11 |
abv illness | 11 |
ngc strain | 11 |
dates extracts | 11 |
denv activity | 11 |
culture supernatant | 11 |
sample preparation | 11 |
specific primers | 11 |
protein response | 11 |
clinical isolates | 11 |
creative commons | 11 |
recombinant protein | 11 |
dhf epidemics | 11 |
confirmed cases | 11 |
flavivirus diseases | 11 |
virus yield | 11 |
denv infected | 11 |
viral variants | 11 |
dengue vector | 11 |
subunit vaccine | 11 |
cytokine production | 11 |
mosaic virus | 11 |
inhibit denv | 11 |
i interferon | 11 |
small interfering | 11 |
competing interests | 11 |
afi cases | 11 |
molecular biology | 11 |
genotype iv | 11 |
general population | 11 |
detection limit | 11 |
serial dilutions | 11 |
accession number | 11 |
signaling pathways | 11 |
infection among | 11 |
rna helicase | 11 |
endothelial cell | 11 |
genomic rna | 11 |
two viruses | 11 |
target cells | 11 |
least two | 11 |
serotype denv | 11 |
virus adsorption | 11 |
mosquito cell | 11 |
neutralising antibodies | 11 |
intracellular pathogens | 10 |
viral envelope | 10 |
replication organelles | 10 |
dengue viremia | 10 |
case report | 10 |
blotting analysis | 10 |
fc receptor | 10 |
congenital anomalies | 10 |
secreted ns | 10 |
also used | 10 |
autophagy pathway | 10 |
severe clinical | 10 |
complement receptors | 10 |
disease burden | 10 |
mouth disease | 10 |
using denv | 10 |
small number | 10 |
virus genome | 10 |
weight loss | 10 |
based assays | 10 |
positive dengue | 10 |
er membranes | 10 |
viral entry | 10 |
neutralization assay | 10 |
deficient mice | 10 |
barr virus | 10 |
smp peptide | 10 |
infection may | 10 |
borne viruses | 10 |
mosquito vector | 10 |
well plate | 10 |
immunofluorescence assay | 10 |
secondary structure | 10 |
host factor | 10 |
endemic regions | 10 |
will occur | 10 |
results indicate | 10 |
host proteins | 10 |
infection induces | 10 |
cells using | 10 |
weeks old | 10 |
endogenous ifitm | 10 |
also reported | 10 |
antibodydependent enhancement | 10 |
future studies | 10 |
thermo fisher | 10 |
zika syndrome | 10 |
growth medium | 10 |
new insights | 10 |
virus strain | 10 |
hcv replication | 10 |
luciferase activity | 10 |
suspected cases | 10 |
rna levels | 10 |
acid sequence | 10 |
rna decay | 10 |
increased risk | 10 |
previous studies | 10 |
warning signs | 10 |
viral diseases | 10 |
host immune | 10 |
symptomatic abv | 10 |
cells via | 10 |
sequence alignment | 10 |
lipid metabolism | 10 |
er lumen | 10 |
clinical performance | 10 |
conserved regions | 10 |
gene sequences | 10 |
denv serotyping | 10 |
intradomestic controls | 10 |
glycosylation site | 10 |
congenital zikv | 10 |
host innate | 10 |
membrane alterations | 10 |
inflammatory cytokines | 10 |
green i | 10 |
previously shown | 10 |
abv infection | 10 |
autochthonous cases | 10 |
data showed | 10 |
determine whether | 10 |
active surveillance | 10 |
regression analysis | 10 |
abv transmission | 10 |
er membrane | 10 |
infection model | 10 |
epidemiological impact | 10 |
acute denv | 10 |
epithelial cells | 9 |
overlay medium | 9 |
urgently needed | 9 |
double membrane | 9 |
blood centers | 9 |
symptom onset | 9 |
severe forms | 9 |
blood meal | 9 |
dengue prevention | 9 |
dhf cases | 9 |
primary dengue | 9 |
secondary dengue | 9 |
denv strains | 9 |
ebola virus | 9 |
institutional review | 9 |
visualized using | 9 |
acid sequences | 9 |
rna copy | 9 |
whole blood | 9 |
protective immunity | 9 |
subgenomic replicon | 9 |
reported cases | 9 |
binding lectin | 9 |
cell entry | 9 |
feline infectious | 9 |
red blood | 9 |
assembly sites | 9 |
extracellular traps | 9 |
will also | 9 |
day pos | 9 |
trial will | 9 |
response pattern | 9 |
replicon rna | 9 |
online version | 9 |
medical university | 9 |
applied biosystems | 9 |
human dendritic | 9 |
uninfected cells | 9 |
global spread | 9 |
lamp product | 9 |
induced autophagosomes | 9 |
viral strains | 9 |
population controls | 9 |
recipient hela | 9 |
like receptor | 9 |
antiviral agent | 9 |
differential diagnosis | 9 |
ifitm expression | 9 |
class ii | 9 |
inflammatory response | 9 |
natural compounds | 9 |
evolutionary genetics | 9 |
washed twice | 9 |
per well | 9 |
borne disease | 9 |
transmission electron | 9 |
dengue transmission | 9 |
control sirna | 9 |
cohort study | 9 |
throughput screening | 9 |
copy numbers | 9 |
previously reported | 9 |
clinical outcomes | 9 |
vaccine candidate | 9 |
multiplex real | 9 |
infected mice | 9 |
findings suggest | 9 |
different denv | 9 |
crispr cas | 9 |
symptomatic cases | 9 |
analyzed using | 9 |
viremia titer | 9 |
controlled trial | 9 |
extracellular environment | 9 |
human cytomegalovirus | 9 |
poc pon | 9 |
wnv cases | 9 |
infectious peritonitis | 9 |
may contribute | 9 |
genotypes i | 9 |
dengue dengue | 9 |
potential risk | 9 |
clinical course | 9 |
infectious agents | 9 |
identified factors | 9 |
viral factors | 9 |
human complement | 9 |
stimulated genes | 9 |
dengue diagnosis | 9 |
borne flaviviruses | 9 |
incubation period | 9 |
epidemic potential | 9 |
antiviral immunity | 9 |
sequence diversity | 9 |
electron microscopic | 9 |
goat anti | 9 |
hours post | 9 |
progeny denv | 9 |
vaccinia virus | 9 |
sanofi pasteur | 9 |
denv host | 9 |
eye pain | 9 |
commercially available | 9 |
human disease | 9 |
effective antiviral | 9 |
fubc gene | 9 |
viral replicase | 9 |
emory university | 9 |
containing exosomes | 9 |
serotype correlate | 9 |
inhibitory concentration | 9 |
innate antiviral | 9 |
obtained using | 9 |
medium containing | 9 |
graphpad prism | 9 |
se asia | 9 |
mammalian cell | 9 |
american journal | 9 |
yucatan state | 9 |
i clinical | 9 |
denv amplification | 9 |
human immune | 8 |
publication bias | 8 |
protein band | 8 |
among patients | 8 |
mif rna | 8 |
pcr using | 8 |
denv igg | 8 |
pockit combo | 8 |
persistent infection | 8 |
enhancing antibodies | 8 |
vero cell | 8 |
negative controls | 8 |
affinity maturation | 8 |
highest concentration | 8 |
igg antibody | 8 |
inhibits denv | 8 |
total rna | 8 |
zikv rna | 8 |
pr peptide | 8 |
bone marrow | 8 |
prevalence rate | 8 |
positive samples | 8 |
cellular immune | 8 |
cell type | 8 |
study reported | 8 |
mif transcription | 8 |
single open | 8 |
geographic distribution | 8 |
humoral immune | 8 |
antibody dependent | 8 |
chronic disease | 8 |
mortality rate | 8 |
crystal structure | 8 |
albopictus mosquitoes | 8 |
virus disease | 8 |
rna extraction | 8 |
drug development | 8 |
ros production | 8 |
serine protease | 8 |
human diseases | 8 |
like illness | 8 |
encephalomyocarditis virus | 8 |
proteins ns | 8 |
estimated million | 8 |
niclosamide treatment | 8 |
western blot | 8 |
cases reported | 8 |
phylogenetic trees | 8 |
dna vaccines | 8 |
viral protease | 8 |
different serotypes | 8 |
transcription factors | 8 |
southern france | 8 |
envelope domain | 8 |
virus life | 8 |
igg titer | 8 |
post transfection | 8 |
induces autophagy | 8 |
data analysis | 8 |
two independent | 8 |
carbon electrode | 8 |
foci forming | 8 |
urban areas | 8 |
mononuclear phagocytes | 8 |
million people | 8 |
calculated using | 8 |
imported cases | 8 |
stimulated gene | 8 |
protease activity | 8 |
impedimetric cell | 8 |
using reverse | 8 |
santa cruz | 8 |
positive cells | 8 |
pcr amplification | 8 |
core protein | 8 |
significant reduction | 8 |
igm elisa | 8 |
recipient cells | 8 |
critical review | 8 |
virus isolation | 8 |
antiviral agents | 8 |
coding region | 8 |
oxidative stress | 8 |
denv cases | 8 |
heparan sulfate | 8 |
cell cultures | 8 |
early stages | 8 |
phase ii | 8 |
significantly reduced | 8 |
induced membrane | 8 |
low levels | 8 |
severe form | 8 |
standard curve | 8 |
analysis showed | 8 |
yap island | 8 |
cell immunity | 8 |
complement system | 8 |
critical role | 8 |
golgi apparatus | 8 |
viral titers | 8 |
statistical analyses | 8 |
biological control | 8 |
high sensitivity | 8 |
brucella spp | 8 |
large outbreak | 8 |
fold serial | 8 |
step rt | 8 |
review board | 8 |
diabetes mellitus | 8 |
control groups | 8 |
three times | 8 |
antiviral efficacy | 8 |
buffered saline | 8 |
nonhuman primates | 8 |
dengue illness | 8 |
inflammatory responses | 8 |
national university | 8 |
sense rna | 8 |
antiviral compounds | 8 |
care hospital | 8 |
complex glycans | 8 |
equal volume | 8 |
insulated isothermal | 8 |
commons attribution | 8 |
lethal infection | 8 |
virus infected | 8 |
participants years | 8 |
vicenza province | 8 |
laboratory testing | 8 |
abdominal pain | 8 |
type lectin | 8 |
infectious denv | 8 |
single dose | 8 |
known denv | 8 |
study participants | 8 |
chronic diseases | 8 |
high throughput | 8 |
virus titers | 8 |
many viruses | 8 |
recorded waypoints | 8 |
dengue endemic | 8 |
viruses using | 8 |
intracellular viral | 8 |
humidified incubator | 8 |
disease outcome | 8 |
virus inhibition | 8 |
mosquito species | 8 |
tcid assay | 8 |
till hr | 8 |
i ii | 7 |
expression vector | 7 |
mosquito bites | 7 |
protective efficacy | 7 |
epidemic arboviral | 7 |
geographical distribution | 7 |
study found | 7 |
specific virus | 7 |
late stage | 7 |
igg immune | 7 |
rhesus monkeys | 7 |
final concentration | 7 |
pcr reactions | 7 |
measles vaccine | 7 |
rapid diagnostic | 7 |
glycosylation sites | 7 |
continuous treatment | 7 |
cinanserin hydrochloride | 7 |
infected human | 7 |
mosquito breeding | 7 |
reaction denv | 7 |
culture supernatants | 7 |
ii ifn | 7 |
genotype database | 7 |
similar clinical | 7 |
transfusion risk | 7 |
polypyrimidine tract | 7 |
endothelial permeability | 7 |
also showed | 7 |
rubella virus | 7 |
south korea | 7 |
denv outbreaks | 7 |
combo system | 7 |
viral titer | 7 |
currently available | 7 |
recombinant virus | 7 |
graphpad software | 7 |
human skin | 7 |
integral membrane | 7 |
denv protein | 7 |
crude venom | 7 |
elevated levels | 7 |
abv cases | 7 |
enhances virus | 7 |
forming units | 7 |
dengue epidemic | 7 |
joint pain | 7 |
nucleic acids | 7 |
four days | 7 |
febrile illnesses | 7 |
hcv activity | 7 |
disease outbreak | 7 |
causes dengue | 7 |
natural products | 7 |
crystal violet | 7 |
limited settings | 7 |
rnai pathway | 7 |
family members | 7 |
potential therapeutic | 7 |
small sample | 7 |
viral translation | 7 |
structural basis | 7 |
transmission cycle | 7 |
central role | 7 |
flavivirus kunjin | 7 |
cellular rna | 7 |
viral life | 7 |
ns hexamer | 7 |
disease prevention | 7 |
ifn production | 7 |
induced cytopathogenesis | 7 |
significant difference | 7 |
infected vero | 7 |
southern china | 7 |
health care | 7 |
cycle sequencing | 7 |
indirect immunofluorescence | 7 |
human igg | 7 |
article distributed | 7 |
inflammatory macrophages | 7 |
coronavirus replication | 7 |
zikv particles | 7 |
global burden | 7 |
takes place | 7 |
secondary antibody | 7 |
mouse igg | 7 |
bc peptides | 7 |
hcv rna | 7 |
two types | 7 |
arbovirus infection | 7 |
newly synthesized | 7 |
ko cells | 7 |
multiplex rt | 7 |
interfering rna | 7 |
human blood | 7 |
experimental design | 7 |
mosquito populations | 7 |
renilla luciferase | 7 |
laboratory confirmation | 7 |
novel reporter | 7 |
viral foci | 7 |
disease pathogenesis | 7 |
denv antibodies | 7 |
human population | 7 |
mediated endocytosis | 7 |
specific antiviral | 7 |
extracellular milieu | 7 |
clinical characteristics | 7 |
exclude concomitant | 7 |
final manuscript | 7 |
blood donation | 7 |
derived macrophages | 7 |
hepatitis virus | 7 |
incubated overnight | 7 |
mediated enhancement | 7 |
mouse monoclonal | 7 |
ifn receptor | 7 |
enhance dengue | 7 |
epidemic areas | 7 |
pacific region | 7 |
induce autophagy | 7 |
protects mice | 7 |
time spent | 7 |
cleavage site | 7 |
fold reduction | 7 |
chikungunya viruses | 7 |
sialic acid | 7 |
virion surface | 7 |
hek cells | 7 |
complex formation | 7 |
neurological complications | 7 |
associated protein | 7 |
global threat | 7 |
virus neutralizing | 7 |
rna polymerases | 7 |
randomized controlled | 7 |
bl mice | 7 |
genetics analysis | 7 |
pcr amplicons | 7 |
pcr products | 7 |
hcv ns | 7 |
ns region | 7 |
care diagnostics | 7 |
ade infection | 7 |
different stages | 7 |
will provide | 7 |
breast milk | 7 |
selection pressures | 7 |
endosomal acidification | 7 |
concomitant infections | 7 |
four antigenically | 7 |
dimensional architecture | 7 |
high resolution | 7 |
widely used | 7 |
south pacific | 7 |
virus replicon | 7 |
different cell | 7 |
following infection | 7 |
mini kit | 7 |
high level | 7 |
specific detection | 7 |
single strand | 7 |
disease outbreaks | 7 |
antibody titers | 7 |
induced inflammasome | 7 |
authors read | 7 |
virus output | 7 |
early diagnosis | 7 |
phylogenetic relationships | 7 |
antigenic sin | 7 |
polyprotein processing | 7 |
chikv infections | 7 |
insecticide resistance | 7 |
fatty acid | 7 |
isothermal pcr | 7 |
protein interactions | 7 |
vero slam | 7 |
human peripheral | 7 |
interests include | 7 |
first year | 7 |
endothelial glycocalyx | 7 |
scientificreports www | 7 |
human movement | 7 |
denv may | 7 |
mediated neutralization | 7 |
flavivirus ns | 7 |
vascular leak | 7 |
surveillance system | 7 |
plaque forming | 7 |
autophagosome formation | 7 |
ns rt | 7 |
antiviral responses | 7 |
prevalence rates | 7 |
pbs buffer | 7 |
written informed | 7 |
seven nonstructural | 7 |
cd spectrum | 7 |
study also | 7 |
including denv | 7 |
wide range | 7 |
molecular weight | 7 |
denv viral | 7 |
autophagic vesicles | 7 |
original antigenic | 7 |
patients may | 7 |
least three | 7 |
denv life | 7 |
cells per | 7 |
expressing cells | 7 |
children aged | 7 |
analysis revealed | 7 |
receptor type | 7 |
whole cell | 7 |
sirnas targeting | 7 |
luciferase gene | 7 |
orv illness | 7 |
genomic sequences | 7 |
mhc class | 7 |
th day | 6 |
human cells | 6 |
may play | 6 |
zikv transmission | 6 |
molecular diagnosis | 6 |
fluorescent protein | 6 |
central system | 6 |
virus subgenomic | 6 |
sirna transfection | 6 |
live denv | 6 |
epidemiological characteristics | 6 |
cell activation | 6 |
viremic patients | 6 |
four different | 6 |
autophagosomal membranes | 6 |
assay showed | 6 |
genbank af | 6 |
depth analysis | 6 |
beet yellows | 6 |
golgi network | 6 |
clinical specimens | 6 |
linear correlation | 6 |
cytotoxic effects | 6 |
similar results | 6 |
proteasome pathway | 6 |
blood products | 6 |
less conserved | 6 |
selectivity index | 6 |
cruz biotechnology | 6 |
human antibodies | 6 |
protein production | 6 |
denv outbreak | 6 |
like particles | 6 |
virus molecular | 6 |
borne transmission | 6 |
asian genotype | 6 |
clinical isolate | 6 |
zikv epidemic | 6 |
highly specific | 6 |
nonspecific amplification | 6 |
essential medium | 6 |
containing exosome | 6 |
access article | 6 |
proinflammatory cytokines | 6 |
seven non | 6 |
terminal complement | 6 |
evans blue | 6 |
leishmania major | 6 |
igg elisa | 6 |
potent antiviral | 6 |
serotypes denv | 6 |
female mice | 6 |
east africa | 6 |
rna molecules | 6 |
slam cells | 6 |
targeted indoor | 6 |
sequence analysis | 6 |
reactive antibodies | 6 |
national center | 6 |
recombinant dengue | 6 |
presenting cells | 6 |
virus using | 6 |
small rna | 6 |
viral antigens | 6 |
using primers | 6 |
type envelope | 6 |
human herpesvirus | 6 |
medical research | 6 |
perinatal transmission | 6 |
emerging viruses | 6 |
mobility patterns | 6 |
nm diameter | 6 |
denv replicates | 6 |
protease cleavage | 6 |
nonstructural glycoprotein | 6 |
envelope proteins | 6 |
sars cov | 6 |
may explain | 6 |
essential role | 6 |
study protocol | 6 |
viral loads | 6 |
aedes spp | 6 |
vast majority | 6 |
seven days | 6 |
reporter cell | 6 |
post transfusion | 6 |
membrane compartments | 6 |
accession numbers | 6 |
flavivirus genus | 6 |
co choco | 6 |
denv production | 6 |
rna samples | 6 |
cell fitness | 6 |
abv case | 6 |
monoclonal anti | 6 |
wnv replication | 6 |
rna processing | 6 |
case definitions | 6 |
coronavirus disease | 6 |
molecular characterization | 6 |
ade assay | 6 |
anti denv | 6 |
broad spectrum | 6 |
signal transduction | 6 |
intracellular pools | 6 |
residual insecticides | 6 |
cerebrospinal fluid | 6 |
multiple comparison | 6 |
disulfide bonds | 6 |
specific anti | 6 |
soluble protein | 6 |
patients presenting | 6 |
conjugated goat | 6 |
heterogeneous nuclear | 6 |
inhibits dengue | 6 |
enveloped virus | 6 |
newly developed | 6 |
cells dengue | 6 |
imported dengue | 6 |
green iebased | 6 |
equine encephalitis | 6 |
one study | 6 |
infected mosquitoes | 6 |
automated sample | 6 |
rna detection | 6 |
rna translation | 6 |
dhf epidemic | 6 |
papua new | 6 |
hela uprt | 6 |
hamster kidney | 6 |
increased viral | 6 |
highly immunogenic | 6 |
serological tests | 6 |
denv induces | 6 |
denv patients | 6 |
homology search | 6 |
brain barrier | 6 |
chikv vaccine | 6 |
molecular clock | 6 |
protein gene | 6 |
factors may | 6 |
specific monoclonal | 6 |
receptor binding | 6 |
fatty acids | 6 |
vertebrate hosts | 6 |
natural killer | 6 |
louis encephalitis | 6 |
murray valley | 6 |
reduce dengue | 6 |
ifn signaling | 6 |
brazil zika | 6 |
genetic diversity | 6 |
denv genotype | 6 |
ms ms | 6 |
automated system | 6 |
bc loops | 6 |
first week | 6 |
strain isolated | 6 |
possible association | 6 |
tight junctions | 6 |
selected based | 6 |
reverse primer | 6 |
replicon cells | 6 |
mutant viruses | 6 |
infected aedes | 6 |
san diego | 6 |
patients infected | 6 |
viral ns | 6 |
master mix | 6 |
gene transcription | 6 |
lamp reaction | 6 |
kindly provided | 6 |
global spatial | 6 |
cell membrane | 6 |
sequence identity | 6 |
ribosome entry | 6 |
results demonstrated | 6 |
two major | 6 |
late stages | 6 |
protein domain | 6 |
commonly used | 6 |
sample collection | 6 |
enhance viral | 6 |
entry site | 6 |
mycobacterium tuberculosis | 6 |
new england | 6 |
transmission season | 6 |
fc receptors | 6 |
million dengue | 6 |
human parvovirus | 6 |
linked glycosylation | 6 |
inner mongolia | 6 |
denv diiis | 6 |
proteomic analysis | 6 |
medium supplemented | 6 |
glycoprotein ns | 6 |
including dengue | 6 |
possible role | 6 |
million cases | 6 |
cbx inhibits | 6 |
disease progression | 6 |
local health | 6 |
internal ribosome | 6 |
mean age | 6 |
microplate reader | 6 |
mouse hepatitis | 6 |
acid binding | 6 |
also tested | 6 |
leukemia virus | 6 |
also demonstrated | 6 |
neutralizing monoclonal | 6 |
centralized location | 6 |
thermo scientific | 6 |
dna polymerase | 6 |
igg response | 6 |
signaling pathway | 6 |
laboratory features | 6 |
iipcr reagent | 6 |
health problems | 6 |
nested pcr | 6 |
alkaline phosphatase | 6 |
liquid chromatography | 6 |
ph compartments | 6 |
bacillus thuringiensis | 6 |
vector aedes | 6 |
important mosquito | 6 |
flavivirus replication | 6 |
hexameric ns | 6 |
dengue control | 6 |
two groups | 6 |
replicon rnas | 6 |
viruses date | 6 |
cell epitopes | 6 |
graph pad | 6 |
current knowledge | 6 |
infectious particles | 6 |
north america | 6 |
glycan structures | 6 |
defence system | 6 |
chronic hepatitis | 6 |
stably expressing | 6 |
within days | 6 |
gap junctions | 6 |
three different | 6 |
positive results | 6 |
regulates lipid | 6 |
replication factory | 6 |
primers used | 6 |
luciferase reporter | 6 |
zikv may | 6 |
blood donor | 6 |
structural genes | 6 |
transcriptase pcr | 6 |
gene using | 6 |
previously identified | 6 |
baby hamster | 6 |
even though | 6 |
cell types | 6 |
molecular mass | 6 |
mild dengue | 6 |
living cells | 6 |
ros generation | 6 |
forming unit | 6 |
high incidence | 6 |
control strategies | 6 |
direct virucidal | 6 |
serum levels | 6 |
spatial limits | 6 |
virus challenge | 6 |
cells well | 6 |
adverse events | 6 |
bona fide | 6 |
chikungunya disease | 6 |
drug discovery | 6 |
adaptive immunity | 6 |
birth defects | 6 |
quantitative real | 6 |
amplification method | 6 |
cases per | 6 |
bc peptide | 6 |
valley encephalitis | 6 |
phase iii | 6 |
different types | 6 |
infection also | 6 |
impedance signals | 6 |
among donors | 6 |
classical pathway | 6 |
national institute | 6 |
standard deviation | 6 |
dengue incidence | 6 |
magnetic beads | 6 |
virus capsid | 6 |
cellular receptor | 6 |
results indicated | 6 |
vitro antiviral | 6 |
study shows | 6 |
data indicate | 6 |
commercial tannic | 6 |
skin rash | 6 |
irav ko | 6 |
reduced denv | 6 |
denv proteins | 6 |
copies per | 6 |
containing vesicles | 6 |
antigenically distinct | 6 |
kunjin virus | 6 |
virion maturation | 6 |
older adults | 6 |
dengue case | 6 |
recombinant subunit | 6 |
small rnas | 6 |
high prevalence | 6 |
data collection | 6 |
adult participants | 6 |
denv sequences | 6 |
lamp assays | 6 |
escape mutants | 6 |
autophagy regulates | 6 |
avian influenza | 6 |
uv light | 6 |
intracellular membrane | 6 |
induced vesicles | 6 |
rna transcription | 6 |
hiv infection | 5 |
rna template | 5 |
immune activation | 5 |
several countries | 5 |
study using | 5 |
molecular diagnostic | 5 |
gap junction | 5 |
fatal cases | 5 |
previously infected | 5 |
virus spreads | 5 |
also developed | 5 |
infection via | 5 |
severe dhf | 5 |
bovine viral | 5 |
flow rate | 5 |
research program | 5 |
recent advances | 5 |
dengue illnesses | 5 |
type mice | 5 |
endothelial dysfunction | 5 |
developing countries | 5 |
remains unclear | 5 |
ethics committee | 5 |
ic values | 5 |
enhancing antibody | 5 |
cell growth | 5 |
conserved sequence | 5 |
potent inhibition | 5 |
binding interface | 5 |
supporting information | 5 |
washed three | 5 |
complement component | 5 |
asian i | 5 |
study design | 5 |
amplified products | 5 |
lactate dehydrogenase | 5 |
neighboring countries | 5 |
may provide | 5 |
regulatory factor | 5 |
ifitm cells | 5 |
located within | 5 |
monocytes macrophages | 5 |
widely distributed | 5 |
original author | 5 |
ng ml | 5 |
using ordinary | 5 |
gene silencing | 5 |
virus encephalitis | 5 |
vaccine efficacy | 5 |
first wave | 5 |
yellows virus | 5 |
conserved fusion | 5 |
first identified | 5 |
interferon regulatory | 5 |
amniotic fluid | 5 |
capture elisa | 5 |
magnesium pyrophosphate | 5 |
genbank accession | 5 |
bearing cells | 5 |
transgenic mosquitoes | 5 |
serial dilution | 5 |
human pathogens | 5 |
cellular pathways | 5 |
observational study | 5 |
recent epidemics | 5 |
epidemic situation | 5 |
first report | 5 |
mm nacl | 5 |
adult patients | 5 |
inhibit viral | 5 |
virus associated | 5 |
drosophila melanogaster | 5 |
denv rvps | 5 |
specimens will | 5 |
purified protein | 5 |
glycan structure | 5 |
post onset | 5 |
rna using | 5 |
remains neutral | 5 |
past years | 5 |
df patients | 5 |
per reaction | 5 |
therapeutic intervention | 5 |
like antibodies | 5 |
microbial translocation | 5 |
virus stocks | 5 |
human myeloid | 5 |
findings indicate | 5 |
van den | 5 |
cell infection | 5 |
data mining | 5 |
fixed amount | 5 |
vivo studies | 5 |
copies ml | 5 |
study dengue | 5 |
local mosquito | 5 |
classification system | 5 |
acid changes | 5 |
abc transporter | 5 |
african green | 5 |
effective vaccine | 5 |
infection rate | 5 |
germinal center | 5 |
important roles | 5 |
class iii | 5 |
pathogenic roles | 5 |
specimens collected | 5 |
highly sensitive | 5 |
quantified using | 5 |
complement control | 5 |
acute infection | 5 |
neutralizing human | 5 |
major public | 5 |
productive infection | 5 |
phylogenetic history | 5 |
phylogenetically distinct | 5 |
virion assembly | 5 |
secretory autophagy | 5 |
biotechnology information | 5 |
ph intracellular | 5 |
paired serum | 5 |
qiaamp viral | 5 |
mouse macrophages | 5 |
infectious bronchitis | 5 |
purified fubc | 5 |
high concentrations | 5 |
three denv | 5 |
nearly half | 5 |
function analysis | 5 |
replication inhibition | 5 |
leishmania infantum | 5 |
results obtained | 5 |
urgent need | 5 |
based amplification | 5 |
modified spce | 5 |
denv prm | 5 |
protein inhibits | 5 |
among chinese | 5 |
associated proteins | 5 |
data suggest | 5 |
flavivirus nonstructural | 5 |
sexual transmission | 5 |
positive denv | 5 |
host genetic | 5 |
i index | 5 |
pcr detection | 5 |
samples will | 5 |
tumor necrosis | 5 |
hcl ph | 5 |
denv viruses | 5 |
chikungunya infection | 5 |
buffer containing | 5 |
health authorities | 5 |
protein levels | 5 |
east asia | 5 |
intracellular replication | 5 |
reverse primers | 5 |
relatively high | 5 |
first reported | 5 |
pcr product | 5 |
glycyrrhetinic acid | 5 |
dengue dna | 5 |
anova followed | 5 |
virus propagation | 5 |
open access | 5 |
structural analysis | 5 |
sense single | 5 |
cell receptors | 5 |
will quantify | 5 |
travel history | 5 |
carbenoxolone disodium | 5 |
autophagic machinery | 5 |
neutralization testing | 5 |
observations related | 5 |
detection rate | 5 |
complete genomic | 5 |
epidemiological surveillance | 5 |
loopmediated isothermal | 5 |
flow icts | 5 |
least one | 5 |
cultured cells | 5 |
fever vaccine | 5 |
epidemiological evidence | 5 |
binding sites | 5 |
live infection | 5 |
abv infections | 5 |
vector competence | 5 |
incidence rate | 5 |
plaque assays | 5 |
three independent | 5 |
per ml | 5 |
protein glycosylation | 5 |
specific pathogen | 5 |
dmv formation | 5 |
histocompatibility complex | 5 |
phylogenetic analyses | 5 |
bronchitis virus | 5 |
adult ae | 5 |
rna level | 5 |
ab responses | 5 |
dengue outbreaks | 5 |
virus protein | 5 |
replication vesicles | 5 |
encephalitis viruses | 5 |
membrane invaginations | 5 |
wild type | 5 |
virus venom | 5 |
macrophage activation | 5 |
disease surveillance | 5 |
enhanced viral | 5 |
also plays | 5 |
among groups | 5 |
dengue classification | 5 |
every year | 5 |
host antiviral | 5 |
accurate diagnosis | 5 |
developed assay | 5 |
significant antiviral | 5 |
us government | 5 |
research interests | 5 |
zikv vaccine | 5 |
transmission routes | 5 |
cytopathic effects | 5 |
neutrophil activation | 5 |
rapid identification | 5 |
survival rate | 5 |
prevalent mosquito | 5 |
soluble complement | 5 |
southeast asian | 5 |
zikv exposure | 5 |
tdv vaccine | 5 |
point mutation | 5 |
respiratory tract | 5 |
developed using | 5 |
langerhans cells | 5 |
first case | 5 |
effective dengue | 5 |
vaccine immunogens | 5 |
enhanced dengue | 5 |
virus replicons | 5 |
si value | 5 |
recently developed | 5 |
jurisdictional claims | 5 |
st tannic | 5 |
denv pathogenesis | 5 |
asian lineage | 5 |
without adjuvant | 5 |
logistic regression | 5 |
potential anti | 5 |
filter unit | 5 |
recent decades | 5 |
inactivated vaccine | 5 |
class i | 5 |
health emergency | 5 |
pattern recognition | 5 |
assay kit | 5 |
also play | 5 |
fusion peptide | 5 |
two distinct | 5 |
lamp results | 5 |
replication compartments | 5 |
phase clinical | 5 |
protein synthesis | 5 |
subsequent infection | 5 |
severe den | 5 |
springer nature | 5 |
control cells | 5 |
federated states | 5 |
laboratory diagnostic | 5 |
conducted using | 5 |
molecular determinants | 5 |
dis doi | 5 |
refractive index | 5 |
proportional hazards | 5 |
denv database | 5 |
rural areas | 5 |
cellular autophagy | 5 |
mice lacking | 5 |
virus via | 5 |
health concern | 5 |
oxygen species | 5 |
ordinary one | 5 |
may increase | 5 |
cell receptor | 5 |
cellular membranes | 5 |
subgenomic replicons | 5 |
common visit | 5 |
complement pathway | 5 |
virus growth | 5 |
evaluated using | 5 |
based rdt | 5 |
using plaque | 5 |
asian countries | 5 |
positioning system | 5 |
research center | 5 |
ade phenomenon | 5 |
following denv | 5 |
necrosis factor | 5 |
derived exosomes | 5 |
light chains | 5 |
protein genes | 5 |
mrna expression | 5 |
french authorities | 5 |
reported previously | 5 |
female mosquitoes | 5 |
quantified peptides | 5 |
attenuated dengue | 5 |
myeloid cells | 5 |
somatic hypermutation | 5 |
asymptomatic blood | 5 |
progeny virus | 5 |
host cellular | 5 |
useful tool | 5 |
intracellular compartments | 5 |
denv titers | 5 |
inactivated measles | 5 |
hr prior | 5 |
large number | 5 |
reduced levels | 5 |
high viral | 5 |
ifitm mrna | 5 |
cellular metabolism | 5 |
like particle | 5 |
type viruses | 5 |
varying degrees | 5 |
extracted using | 5 |
denv detection | 5 |
ifn response | 5 |
dimeric ns | 5 |
golgi complex | 5 |
positivity rate | 5 |
ml respectively | 5 |
nature remains | 5 |
clinical disease | 5 |
mice immunized | 5 |
colombian isolates | 5 |
time monitoring | 5 |
including human | 5 |
dmem supplemented | 5 |
first outbreak | 5 |
virus may | 5 |
virus clearance | 5 |
igm antibody | 5 |
eliminate dengue | 5 |
blood feeding | 5 |
institutional affiliations | 5 |
primary endpoint | 5 |
cell cycle | 5 |
animal reservoirs | 5 |
rhesus macaques | 5 |
human brucellosis | 5 |
vital signs | 5 |
confocal microscopy | 5 |
major histocompatibility | 5 |
sirna knockdown | 5 |
assay using | 5 |
untranslated regions | 5 |
new dengue | 5 |
visit sites | 5 |
fibroblast cells | 5 |
df outbreak | 5 |
particle production | 5 |
salivary glands | 5 |
membranous web | 5 |
microbiol doi | 5 |
system based | 5 |
glycyrrhizic acid | 5 |
silac ratio | 5 |
irav associates | 5 |
continuing global | 5 |
laboratory animals | 5 |
supernatants derived | 5 |
antibody library | 5 |
virus development | 5 |
epidemiological investigation | 5 |
also performed | 5 |
reduce denv | 5 |
mediated translation | 5 |
also detected | 5 |
replication machinery | 5 |
zika viruses | 5 |
cells revealed | 5 |
infected subjects | 5 |
vaccine strategies | 5 |
pan american | 5 |
outbreak pattern | 5 |
alpha beta | 5 |
virus pathogenesis | 5 |
mainly due | 5 |
four clinical | 5 |
fold rise | 5 |
denv genotypes | 5 |
genome release | 5 |
recent denv | 5 |
iot pcr | 5 |
induced vascular | 5 |
routine diagnosis | 5 |
minimum essential | 5 |
year period | 5 |
microscopic study | 5 |
purified ifitm | 5 |
sodium channel | 5 |
total number | 5 |
rna mini | 5 |
formation assay | 5 |
ft tannic | 5 |
distinct serotypes | 5 |
published maps | 5 |
viruses dengue | 5 |
complement regulatory | 5 |
entry inhibitors | 5 |
final volume | 5 |
venom fractions | 5 |
patients suspected | 5 |
blood specimens | 5 |
protease inhibitors | 5 |
passive surveillance | 5 |
follicular dendritic | 5 |
agents among | 5 |
activity assay | 5 |
medical center | 5 |
virus enhances | 5 |
denv mock | 5 |
malaria infections | 5 |
healthy adult | 5 |
epitope mapping | 5 |
purifying selection | 5 |
enzymatic digestion | 5 |
randomly selected | 5 |
neutralization tests | 5 |
global positioning | 5 |
life sciences | 5 |
intracellular membranes | 5 |
erk activation | 5 |
mannose type | 5 |
dsrna molecules | 5 |
tissue damage | 5 |
diarrhea virus | 5 |
burkholderia pseudomallei | 5 |
pcr reaction | 5 |
test results | 5 |
transcription polymerase | 5 |
particles released | 5 |
indicated concentrations | 5 |
heterologous denv | 5 |
units ml | 5 |
without disulfide | 5 |
gated sodium | 5 |
decay pathways | 5 |
heart disease | 5 |
severe infection | 5 |
average diameter | 5 |
human infection | 5 |
infection till | 5 |
activated macrophages | 5 |
viral genomes | 5 |
disease enhancement | 5 |
key component | 5 |
st century | 5 |
cells grown | 5 |
sudden onset | 5 |
epidemic dengue | 5 |
mouse anti | 5 |
nuclear localization | 5 |
autophagy protein | 5 |
approved vaccine | 5 |
prospective studies | 5 |
autophagy induction | 5 |
leishmania mexicana | 5 |
affected areas | 5 |
pcr device | 5 |
linear regression | 5 |
initial denaturation | 5 |
geq ml | 5 |
competent vectors | 5 |
genetic variation | 5 |
mif expression | 5 |
using different | 5 |
symptomatic dengue | 5 |
monkey kidney | 5 |
viral pathogenesis | 5 |
bare spce | 5 |
cytoplasmic rna | 4 |
marburg virus | 4 |
gene region | 4 |
distance cross | 4 |
tetrazolium bromide | 4 |
merck kgaa | 4 |
foci reduction | 4 |
constrained randomization | 4 |
therapeutic strategies | 4 |
mitochondrial ros | 4 |
rnai mechanism | 4 |
prior dengue | 4 |
census tracts | 4 |
eastern china | 4 |
control programs | 4 |
viral strategies | 4 |
nsp proteins | 4 |
nuclear ribonucleoprotein | 4 |
complement complex | 4 |
transmitted dengue | 4 |
better understand | 4 |
control vector | 4 |
denv virus | 4 |
neutralizing activities | 4 |
significant inhibition | 4 |
rnai response | 4 |
reference compounds | 4 |
tetravalent live | 4 |
grey literature | 4 |
sequence information | 4 |
trypanosoma cruzi | 4 |
den vaccine | 4 |
seroprevalence rates | 4 |
sensitive detection | 4 |
cause severe | 4 |
testing samples | 4 |
rapid test | 4 |
million denv | 4 |
evolutionary analysis | 4 |
enhancing activity | 4 |
antibody production | 4 |
likelihood method | 4 |
acute undifferentiated | 4 |
passively transferred | 4 |
like mab | 4 |
clinical laboratory | 4 |
acute toxicity | 4 |
restriction factor | 4 |
expression profiling | 4 |
protein folding | 4 |
samples tested | 4 |
neutralization breadth | 4 |
burnetii infection | 4 |
cell cytoplasm | 4 |
ade activity | 4 |
viral stocks | 4 |
will require | 4 |
blocking virus | 4 |
detection system | 4 |
consensus sequence | 4 |
vector cells | 4 |
pcr methods | 4 |
control using | 4 |
tetravalent vaccine | 4 |
supplemental table | 4 |
million symptomatic | 4 |
currently unknown | 4 |
novel bunyavirus | 4 |
data demonstrated | 4 |
infected mosquito | 4 |
collected dpo | 4 |
standard rna | 4 |
among dengue | 4 |
low ph | 4 |
acute renal | 4 |
chronically infected | 4 |
rheumatoid arthritis | 4 |
based methods | 4 |
free fatty | 4 |
causative agent | 4 |
trop med | 4 |
virus genotype | 4 |
specific antibody | 4 |
autophagy protects | 4 |
transfusion safety | 4 |
mammalian host | 4 |
also shows | 4 |
mediated antiviral | 4 |
complex class | 4 |
infants born | 4 |
measuring neutralizing | 4 |
administrative limits | 4 |
posterior probability | 4 |
rna silencing | 4 |
green monkey | 4 |
early step | 4 |
southern taiwan | 4 |
person transmission | 4 |
pacific islands | 4 |
five times | 4 |
venezuelan equine | 4 |
light chain | 4 |
hypoxic response | 4 |
machinery activated | 4 |
comparison test | 4 |
symptoms including | 4 |
melting temperature | 4 |
ae albopictus | 4 |
conserved residues | 4 |
salivary gland | 4 |
decay accelerating | 4 |
two reviewers | 4 |
csfv ns | 4 |
dengue afi | 4 |
semen samples | 4 |
two denv | 4 |
viral neutralization | 4 |
may affect | 4 |
dhf outbreak | 4 |
host responses | 4 |
extremely high | 4 |
dengue drug | 4 |
induce membrane | 4 |
poliovirus replication | 4 |
via interactions | 4 |
subtropical countries | 4 |
magnetic resonance | 4 |
inhibitory effects | 4 |
lamp reactions | 4 |
viral structural | 4 |
insect technique | 4 |
cellular infection | 4 |
denv seroprevalence | 4 |
mif mrna | 4 |
preventive measures | 4 |
might lead | 4 |
different cells | 4 |
conserved among | 4 |
infected bhk | 4 |
genereach biotech | 4 |
plasmid dna | 4 |
aotus monkeys | 4 |
stimulating factor | 4 |
national institutes | 4 |
dengue among | 4 |
changing epidemiology | 4 |
molecular patterns | 4 |
infected host | 4 |
will need | 4 |
efficient replication | 4 |
suspected congenital | 4 |
transmission seasons | 4 |
wide spectrum | 4 |
different time | 4 |
three mabs | 4 |
hybrid glycans | 4 |
different flaviviruses | 4 |
reference laboratory | 4 |
clinically suspected | 4 |
one hour | 4 |
genetically engineered | 4 |
hystrix brachyura | 4 |
rpmi medium | 4 |
capture enzyme | 4 |
induced dmvs | 4 |
duane gubler | 4 |
active rna | 4 |
transfusion transmitted | 4 |
recent developments | 4 |
conserved region | 4 |
different studies | 4 |
treat dengue | 4 |
viral glycoproteins | 4 |
interferon receptor | 4 |
blood donations | 4 |
may help | 4 |
aligned using | 4 |
qualitative results | 4 |
healthy children | 4 |
variable region | 4 |
carcinoma cells | 4 |
may trigger | 4 |
mean ae | 4 |
dengue dhf | 4 |
vectors aedes | 4 |
also shown | 4 |
sequence homology | 4 |
infectious dose | 4 |
genus hepacivirus | 4 |
human monocytic | 4 |
extracellular denv | 4 |
membrane association | 4 |
published article | 4 |
coronavirus infection | 4 |
infection models | 4 |
diagnostic groups | 4 |
acute stage | 4 |
mitochondrial dna | 4 |
primary infection | 4 |
based neutralization | 4 |
nih program | 4 |
factors associated | 4 |
interim guidelines | 4 |
functional characterization | 4 |
wash buffer | 4 |
close proximity | 4 |
virus rapid | 4 |
replication dengue | 4 |
high fever | 4 |
prm region | 4 |
larvivorous fish | 4 |
arterivirus replication | 4 |
targeting ns | 4 |
detected using | 4 |
unbound virus | 4 |
dengue igg | 4 |
geographical locations | 4 |
reactive oxygen | 4 |
serological assays | 4 |
fatality rate | 4 |
interacting proteins | 4 |
chikv transmission | 4 |
single stranded | 4 |
antiviral immune | 4 |
alternative pathways | 4 |
specific sirnas | 4 |
via lte | 4 |
ross river | 4 |
limited infection | 4 |
using quantitative | 4 |
done using | 4 |
tmb substrate | 4 |
fold dilution | 4 |
native smp | 4 |
specific manner | 4 |
virus control | 4 |
novel antiviral | 4 |
working electrode | 4 |
assay detected | 4 |
murine model | 4 |
will help | 4 |
reactive epitope | 4 |
reactive nitrogen | 4 |
human coronavirus | 4 |
coding sequence | 4 |
microscopy images | 4 |
human hepatoma | 4 |
will use | 4 |
two studies | 4 |
toward denv | 4 |
etiologic agents | 4 |
virus neuroinvasive | 4 |
situ evolution | 4 |
cell pellets | 4 |
following formula | 4 |
evidence indicates | 4 |
immature dengue | 4 |
matched case | 4 |
blood sample | 4 |
first described | 4 |
denv vaccine | 4 |
molecular characteristics | 4 |
reduction assay | 4 |
one serotype | 4 |
dmem medium | 4 |
antibody complexes | 4 |
dna prevalence | 4 |
physical examination | 4 |
well understood | 4 |
transfusion transmission | 4 |
human rhinovirus | 4 |
antigen presenting | 4 |
vaccine based | 4 |
expression level | 4 |
cell supernatants | 4 |
sp viruses | 4 |
intradomestic control | 4 |
like virus | 4 |
west sumatra | 4 |
without fa | 4 |
adult dengue | 4 |
serum complement | 4 |
major cause | 4 |
significant differences | 4 |
exhibited anti | 4 |
siifitm cells | 4 |
double knock | 4 |
neuroinvasive disease | 4 |
protective role | 4 |
net formation | 4 |
naturally occurring | 4 |
surface protein | 4 |
virus isolated | 4 |
human cases | 4 |
green fluorescent | 4 |
virus date | 4 |
therapeutic interventions | 4 |
ns specific | 4 |
prospective cohort | 4 |
kidney cells | 4 |
consent will | 4 |
single mutation | 4 |
integrated approach | 4 |
cellular response | 4 |
identified studies | 4 |
impedance response | 4 |
positive predictor | 4 |
severe human | 4 |
host gene | 4 |
software inc | 4 |
inhibits viral | 4 |
cordata thunb | 4 |
atypical measles | 4 |
viral titres | 4 |
sirna silencing | 4 |
large numbers | 4 |
barre syndrome | 4 |
confidence interval | 4 |
lysosomal fusion | 4 |
conventional plaque | 4 |
direct evidence | 4 |
laboratory tests | 4 |
acid amplification | 4 |
infection imported | 4 |
significantly inhibited | 4 |
attenuated chimeric | 4 |
docking model | 4 |
targeting host | 4 |
sfm medium | 4 |
protein vp | 4 |
clusters will | 4 |
developing world | 4 |
adaptor protein | 4 |
hazards model | 4 |
pilot study | 4 |
case management | 4 |
stranded dna | 4 |
respiratory failure | 4 |
index values | 4 |
mature il | 4 |
like peptide | 4 |
suspected clinically | 4 |
university hospital | 4 |
virus glycosylation | 4 |
culture collection | 4 |
cell debris | 4 |
also provide | 4 |
england biolabs | 4 |
normalized impedance | 4 |
study identified | 4 |
stable luciferase | 4 |
potent neutralization | 4 |
level expression | 4 |
dengue vaccination | 4 |
screening strategies | 4 |
taco mini | 4 |
better understanding | 4 |
endemic epidemic | 4 |
restriction sites | 4 |
diagnostic testing | 4 |
mif production | 4 |
lectin pathway | 4 |
unknown whether | 4 |
google maps | 4 |
low level | 4 |
fubc recombinant | 4 |
data generated | 4 |
dmvs might | 4 |
negative samples | 4 |
cox proportional | 4 |
dendritic cell | 4 |
rna structures | 4 |
tissue injury | 4 |
increase viral | 4 |
innate cellular | 4 |
pfu denv | 4 |
endosomal membrane | 4 |
recombinant fusion | 4 |
classical reporter | 4 |
written consent | 4 |
antigen detection | 4 |
transfection cells | 4 |
atp production | 4 |
years age | 4 |
nile fever | 4 |
threatening dengue | 4 |
virus translation | 4 |
inflammatory cytokine | 4 |
induced lethality | 4 |
kda protein | 4 |
chronic infections | 4 |
nucleotide sequence | 4 |
tlr signaling | 4 |
first evidence | 4 |
safety profile | 4 |
large dengue | 4 |
different groups | 4 |
bootstrap value | 4 |
poliovirus infection | 4 |
grant number | 4 |
central african | 4 |
western hemisphere | 4 |
retrospective movement | 4 |
envelope gene | 4 |
type culture | 4 |
using non | 4 |
clinical studies | 4 |
plaque size | 4 |
chimeric vaccine | 4 |
preloaded extraction | 4 |
mosquito aedes | 4 |
accelerating factor | 4 |
central america | 4 |
synergistic effect | 4 |
control method | 4 |
significant increase | 4 |
infection induced | 4 |
may persist | 4 |
integrated dna | 4 |
based real | 4 |
per person | 4 |
provided evidence | 4 |
pathogen reduction | 4 |
study demonstrates | 4 |
four types | 4 |
host defense | 4 |
complex structures | 4 |
cellular membrane | 4 |
wells containing | 4 |
alternative pathway | 4 |
mexicana infection | 4 |
coxiella burnetii | 4 |
human endothelial | 4 |
fu loop | 4 |
influenza viruses | 4 |
disease spread | 4 |
positive predictors | 4 |
coronavirus infections | 4 |
near poc | 4 |
complement components | 4 |
undifferentiated febrile | 4 |
curve analysis | 4 |
analysis will | 4 |
cultured mosquito | 4 |
median age | 4 |
disease incidence | 4 |
virus activates | 4 |
quenching peptide | 4 |
infection rates | 4 |
flavonoid components | 4 |
clinical cases | 4 |
neutralization assays | 4 |
facs analysis | 4 |
proinflammatory cytokine | 4 |
sterile insect | 4 |
first laboratory | 4 |
single point | 4 |
tackle infectious | 4 |
comparative analysis | 4 |
assay product | 4 |
healthy donors | 4 |
gps coordinates | 4 |
uv illumination | 4 |
african republic | 4 |
adverse effects | 4 |
held pcr | 4 |
day prior | 4 |
protein sample | 4 |
protect mice | 4 |
amplification time | 4 |
complete genome | 4 |
total protein | 4 |
antiviral properties | 4 |
primary denv | 4 |
chikv strain | 4 |
suspected dengue | 4 |
membrane attack | 4 |
new class | 4 |
ade effect | 4 |
autophagy autophagy | 4 |
city blocks | 4 |
severe flavivirus | 4 |
purified inactivated | 4 |
based consensus | 4 |
limited number | 4 |
like antibody | 4 |
metabolic syndrome | 4 |
high affinity | 4 |
cellular homeostasis | 4 |
fever vaccination | 4 |
cd cd | 4 |
negatively stained | 4 |
study population | 4 |
processing bodies | 4 |
assay developed | 4 |
human antibody | 4 |
amplification reaction | 4 |
protein concentration | 4 |